



Harvard Bioscience, Inc. President to Speak at Thomas Weisel Partners Healthcare Tailwinds Conference 2001

HOLLISTON, Mass., March 28 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that David Green, President of Harvard Bioscience, will be a featured speaker at the Thomas Weisel Partners Healthcare Conference 2001 to be held April 2nd and 3rd in San Francisco, California.

The theme of the conference will be the impact of technology on Healthcare. Mr. Green's remarks will cover developments in drug discovery technology and their impact on accelerating drug development.

In this context he will comment on common pitfalls in drug discovery investing, including the risks involved in the science, the technology and the market. Mr. Green will provide an analysis of drug discovery market segments and business models and will compare the advantages of solving the customers problem versus attempting to create breakthrough technology, and the power of brand recognition and distribution capability versus relying solely on patent protection.

The event will be webcast live at approximately 12:30 pm on April the 3rd and can be found at http://www.veracast.com/twp_healthcare_2001/webcasts/46208167.cfm

Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries through its 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, and Germany with sales facilities in France and Canada.

Statements in this release that relate to expectations and objectives of management for future operations of Harvard Bioscience, Inc., or that otherwise relate to future performance, are forward looking statements. Actual results may differ from those projected as a result of product demand, pricing, market acceptance, economic conditions, intellectual property issues, competitive products, risks in product and technology development, and other risks identified in our Securities and Exchange Commission filings. SOURCE Harvard Bioscience, Inc.

CONTACT: Jim Warren, CFO, jwarren@harvardbioscience.com, or David Green, President, dgreen@harvardbioscience.com, or Chane Graziano, CEO, cgraziano@harvardbioscience.com, all of Harvard Bioscience, Inc./

Disclaimer:

The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrences or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience's web site. For Harvard Bioscience's most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at <http://www.sec.gov>.